<?xml version="1.0" encoding="UTF-8"?>
<p id="par0150">Fifty BSAAs possess not only antiviral but also antibacterial activity (
 <xref rid="fig0020" ref-type="fig">Figure 4</xref>; Table S1) (
 <xref rid="bib0420" ref-type="bibr">Schor and Einav, 2018</xref>). Moreover, 13 of the 50 agents are approved as antibiotics (2 withdrawn). These agents with dual activity could be used for treatment of viral and bacterial co-infections or for the protection of patients from the secondary infections. For example, azithromycin could be used against FLUAV and 
 <italic>Chlamydophila pneumoniae</italic>, 
 <italic>Haemophilus influenzae</italic>, 
 <italic>Mycoplasma pneumoniae</italic> or 
 <italic>Streptococcus pneumoniae</italic> infections (NCT01779570) (
 <xref rid="bib0290" ref-type="bibr">Mandell et al., 2007</xref>).
</p>
